COVID-19 vaccination-associated ipsilateral supraclavicular lymphadenopathy

Area of Science:

• Immunology
• Infectious Diseases
• Oncology

Background:

• Recent advancements in vaccine technology have led to widespread administration of COVID-19 vaccines.
• Lymphadenopathy, or swollen lymph nodes, is a recognized, albeit often transient, side effect of various vaccinations.
• Distinguishing vaccine-induced lymphadenopathy from other causes, such as malignancy, is critical for patient care.

Purpose of the Study:

• To elucidate the characteristics and clinical implications of lymphadenopathy observed after COVID-19 vaccination.
• To provide guidance for clinicians managing patients presenting with lymphadenopathy post-vaccination.
• To differentiate vaccine-related lymphadenopathy from concerning underlying pathologies.

Main Methods:

• Systematic review of literature on COVID-19 vaccine-associated lymphadenopathy.
• Analysis of case reports and clinical series detailing lymph node changes post-vaccination.
• Review of imaging findings and pathological reports related to vaccine-induced lymphadenopathy.

Main Results:

• Lymphadenopathy is a frequent adverse event following COVID-19 vaccination, typically affecting axillary or cervical nodes.
• The onset is usually within days to weeks post-vaccination, with a median duration of several weeks.
• Imaging may show enlarged nodes, sometimes with a heterogeneous appearance, mimicking metastatic disease.

Conclusions:

• Vaccine-associated lymphadenopathy is generally benign and self-limiting.
• Awareness of this phenomenon can prevent misdiagnosis and unnecessary invasive procedures.
• A high index of suspicion and careful clinical correlation are essential when evaluating post-vaccination lymphadenopathy.